The partnership says that it will launch the drug in the European Union on or after October 16, 2018.
Today, Mylan and its partner Fujifilm Kyowa Kirin Biologics announced that the European Commission has granted marketing authorization to Hulio, the partnerships’ adalimumab biosimilar referencing Humira. The biosimilar received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the molecule, FKB327, in July 2018.
The authorization applies to all 28 EU member states, as well as the European Economic Area states, for all indications of the reference Humira.
Mylan President Rajiv Malik commented, “We’re very pleased with the decision of the European Commission to grant marketing authorization for Hulio. This is the fourth product that Mylan will be bringing to market in the area of complex generics and biosimilars, and we’re proud to be a leader in the market formation. We’ve made great progress with Fujifilm Kyowa Kirin Biologics and look forward to continuing this important collaboration.”
The partnership says that it will launch the drug on or after October 16, 2018; in a statement, the companies revealed that Fujifilm Kyowa Kirin has obtained a nonexclusive royalty license with Humira maker, AbbVie, for the use and sale of adalimumab in Europe, and that Mylan has a sublicense. Mylan has previously announced a settlement with AbbVie that covered only Mylan’s right to market a biosimilar adalimumab in ex-European territories, including the United States, starting in July 2023.
Hulio will join a widening group of adalimumab biosimilars entering the European marketplace next month; Samsung Bioepis and Biogen stuck a deal with AbbVie in April 2018 that will allow them to launch their Imraldi on October 16, and Amgen reached a similar settlement in 2017 that will allow it to enter the market on the same date as Imraldi.
Health systems in Europe are already preparing to introduce biosimilar adalimumab and reap what they hope will be a substantial cost savings; the United Kingdom’s National Health Service, for one, has implemented a working group to provide oversight on using the best-value adalimumab using a commissioning framework that launched in 2017. The framework proposes that at least 90% of patients new to treatment and 80% of patients currently receiving treatment be prescribed the best-value biologic within 12 months of the launch of a biosimilar for a given biologic therapy.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
2 Commerce Drive
Cranbury, NJ 08512